Meeting
2013 Breast Cancer Symposium
Biomarkers predictive for pathologic response to neoadjuvant docetaxel/cyclophosphamide chemotherapy in primary breast cancer.
Authors
Kazuhiro Shimada
Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A
Track
Local/Regional Therapy,Risk Assessment, Prevention, Detection, and Screening
Sub Track
High Risk
Citation
J Clin Oncol 31, 2013 (suppl 26; abstr 42)
DOI
10.1200/jco.2013.31.26_suppl.42
Abstract #
42
Poster Bd #
D2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study.
First Author: Takashi Ishikawa
Poster
2021 ASCO Annual Meeting
Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.
First Author: Ignacio Ortego
Poster
2015 ASCO Annual Meeting
Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC).
First Author: Tarek M. A. Abdel-Fatah
First Author: Mireia Margeli